Actionable insights straight to your inbox


Agenus Closes Immuno-Oncology Deal with Gilead

$150 million up front + up to $1.7 billion in milestone payments.
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
Shares in volatile small-cap Agenus (AGEN) leapt on Monday following news that the company had reached a deal with Merck (MRK) to partner in the “discovery and development of therapeutic